Cardiovascular risks associated with protease inhibitors for the treatment of HIV
- Resource Type
- Authors
- Caroline A. Sabin; Lene Ryom; Camilla Ingrid Hatleberg
- Source
- Expert opinion on drug safety. 20(11)
- Subject
- Oncology
medicine.medical_specialty
medicine.medical_treatment
Atazanavir Sulfate
Human immunodeficiency virus (HIV)
HIV Infections
Disease
030204 cardiovascular system & hematology
medicine.disease_cause
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Animals
Humans
Pharmacology (medical)
Darunavir
Dyslipidemias
Randomized Controlled Trials as Topic
Protease
business.industry
General Medicine
HIV Protease Inhibitors
medicine.disease
Atherosclerosis
Atazanavir
Increased risk
Cardiovascular Diseases
Heart Disease Risk Factors
030220 oncology & carcinogenesis
business
Dyslipidemia
medicine.drug
- Language
- ISSN
- 1744-764X
Introduction: Cumulative use of some first-generation protease inhibitors has been associated with higher rates of dyslipidemia and increased risk of cardiovascular disease. The protease inhibitors...